First, genetic variants may influence the efficacy of SSRIs in treating major depression and other psychiatric disorders, as exemplified by a polymorphism of the SCL6A4 gene that encodes the sodium-dependent serotonin transporter (5-hydroythyptamine transporter). Here, SLC6A4 is linked to psychiatric disorder.